BDSX
Biodesix, Inc. NASDAQ Listed Oct 28, 2020$17.35
+3.21%
vs $16.81
Mkt Cap $131.0M
52w Low $5.01
85.8% of range
52w High $19.40
50d MA $14.08
200d MA $10.85
P/E (TTM)
-4.3x
EV/EBITDA
—
P/B
—
Debt/Equity
-29.6x
ROE
1430.6%
P/FCF
-5.6x
RSI (14)
64.70
ATR (14)
$1.07
Beta
0.57
50d MA
$14.08
200d MA
$10.85
Avg Volume
54.0K
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
2970 Wilderness Place · Boulder, CO 80301 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | -1.13 | -0.81 | +28.3% | 11.27 | +19.8% | +32.6% | +0.4% | +3.1% | -1.0% | +5.2% | — |
| Feb 26, 2026 | AMC | -1.05 | -0.49 | +53.3% | 14.22 | +4.0% | +7.8% | +2.7% | -1.6% | -1.3% | +3.7% | — |
| Nov 3, 2025 | AMC | -1.60 | -1.16 | +27.5% | 6.34 | +11.4% | +19.9% | +13.2% | -9.4% | -0.8% | -2.5% | — |
| Aug 7, 2025 | AMC | -1.40 | -1.60 | -14.3% | 8.94 | -8.3% | -10.4% | -2.5% | +5.2% | -6.7% | +3.5% | — |
| May 13, 2025 | AMC | -0.08 | -0.08 | +0.0% | 7.18 | -16.3% | -38.7% | +0.0% | +36.8% | +0.0% | -10.0% | — |
| Mar 3, 2025 | AMC | -0.07 | -0.06 | +14.3% | 14.26 | -10.6% | +1.0% | +20.8% | -2.3% | +1.4% | -6.4% | — |
| Nov 1, 2024 | AMC | -0.08 | -0.07 | +12.5% | 26.00 | +13.8% | +6.9% | -3.6% | -0.7% | +0.0% | +3.0% | — |
| Aug 7, 2024 | AMC | -0.09 | -0.08 | +11.1% | 31.80 | +3.8% | +3.1% | -3.0% | +1.3% | +6.8% | +0.0% | — |
| May 8, 2024 | AMC | -0.15 | -0.14 | +6.7% | 31.00 | -2.6% | +0.0% | +1.9% | -3.8% | -1.3% | +2.0% | — |
| Mar 1, 2024 | AMC | -0.11 | -0.10 | +9.1% | 31.60 | +1.3% | -1.9% | -7.1% | +6.2% | -2.0% | -1.3% | — |
| Nov 7, 2023 | AMC | -0.15 | -0.12 | +20.0% | 29.60 | -2.0% | -10.1% | -6.4% | -3.6% | +8.3% | -2.3% | — |
| Aug 7, 2023 | AMC | -0.21 | -0.17 | +19.0% | 30.80 | +0.0% | +3.9% | -15.6% | -3.7% | +6.9% | +5.1% | — |
| May 11, 2023 | AMC | -0.26 | -0.24 | +7.7% | 34.20 | -5.3% | -12.3% | -3.3% | -13.4% | -3.6% | -5.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15 | H.C. Wainwright | Initiates | Buy | $26 | $15.06 | $15.87 | +5.4% | +3.6% | -1.7% | -0.7% | +10.4% | — |
| Feb 27 | William Blair | Upgrade | Market Perform → Outperform | — | $14.22 | $14.79 | +4.0% | +7.8% | +2.7% | -1.6% | -1.3% | +3.7% |
| Feb 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.45 | $11.53 | +0.7% | +11.6% | -1.6% | +1.4% | +3.5% | -3.2% |
| Sep 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.73 | $6.69 | -0.6% | +5.9% | +0.3% | +13.0% | +3.8% | -4.5% |
| May 21 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $5.42 | $7.87 | +45.2% | +45.8% | -9.9% | -3.8% | +1.2% | -1.0% |
| May 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.18 | $6.01 | -16.3% | -38.7% | +0.0% | +36.8% | +0.0% | -10.0% |
| May 14 | Craig-Hallum | Maintains | Buy → Buy | — | $7.18 | $6.01 | -16.3% | -38.7% | +0.0% | +36.8% | +0.0% | -10.0% |
| May 14 | Lake Street | Maintains | Buy → Buy | — | $7.18 | $6.01 | -16.3% | -38.7% | +0.0% | +36.8% | +0.0% | -10.0% |
| May 14 | William Blair | Downgrade | Outperform → Market Perform | — | $7.18 | $6.01 | -16.3% | -38.7% | +0.0% | +36.8% | +0.0% | -10.0% |
| Apr 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.45 | $11.99 | +4.7% | -6.5% | -0.2% | -1.6% | -1.5% | -8.4% |
| Mar 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $31.60 | $32.00 | +1.3% | -1.9% | -7.1% | +6.2% | -2.0% | -1.3% |
| Dec 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $30.00 | $30.80 | +2.7% | +6.0% | -1.9% | +1.9% | -1.3% | +0.6% |
| May 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $30.20 | $30.20 | +0.0% | +6.3% | +13.4% | -7.7% | +1.2% | -6.5% |
| Apr 20 | TD Cowen | Maintains | Outperform → Outperform | — | $28.10 | $28.00 | -0.4% | +10.3% | +11.0% | -5.2% | -10.4% | +6.8% |
| Nov 17 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $133.80 | $131.40 | -1.8% | -2.4% | -1.1% | -1.2% | -5.2% | +4.0% |
| May 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $295.00 | $280.00 | -5.1% | -11.8% | -3.2% | +0.2% | -3.8% | +4.1% |
| Mar 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $474.60 | $475.40 | +0.2% | -4.6% | -1.7% | -3.8% | -5.7% | -9.8% |
| Feb 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $485.60 | $509.60 | +4.9% | -0.6% | -1.5% | -1.8% | -6.3% | +1.2% |
| Nov 23 | William Blair | Maintains | Outperform → Outperform | — | $341.80 | $340.40 | -0.4% | +3.3% | +1.0% | +0.8% | -5.7% | +5.9% |
| Nov 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $341.80 | $340.40 | -0.4% | +3.3% | +1.0% | +0.8% | -5.7% | +5.9% |
No insider trades available.
8-K
Biodesix, Inc. -- 8-K Filing
Biodesix stockholders overwhelmingly ratified KPMG LLP as independent auditor for 2026, with 8.7 million votes in favor and minimal opposition, ensuring continued audit oversight.
May 20
8-K · 2.02
!! High
Biodesix, Inc. -- 8-K 2.02: Earnings Results
Biodesix reported quarterly earnings results; investors should review the full press release for revenue, profitability metrics, and updated guidance to assess financial performance.
May 4
8-K
Biodesix, Inc. -- 8-K Filing
Biodesix reported strong Q4 2025 results with $28.8 million in revenue and 83% gross margin, demonstrating solid operational performance for the diagnostic solutions company.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Aigh Capital Management Llc | 758,328 | $11M | New | Mar 2026 |
| 2 | Telemark Asset Management, Llc | 489,824 | $7M | Added | Mar 2026 |
| 3 | Aberdeen Group Plc | 458,438 | $7M | Added | Mar 2026 |
| 4 | Soleus Capital Management, L.p. | 416,599 | $6M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 255,161 | $4M | New | Mar 2026 |
| 6 | Marshall Wace, Llp | 141,636 | $2M | New | Mar 2026 |
| 7 | Essex Investment Management Co Llc | 132,086 | $2M | New | Mar 2026 |
| 8 | Stempoint Capital Lp | 70,004 | $1M | New | Mar 2026 |
| 9 | Two Sigma Investments, Lp | 45,231 | $656K | New | Mar 2026 |
| 10 | Sei Investments Co | 43,024 | $624K | New | Mar 2026 |
| 11 | Legato Capital Management Llc | 41,174 | $597K | New | Mar 2026 |
| 12 | Ubs Group Ag | 36,808 | $534K | New | Mar 2026 |
| 13 | Blair William & Co/il | 27,583 | $400K | New | Mar 2026 |
| 14 | Millennium Management | 24,006 | $348K | New | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 23,090 | $335K | New | Mar 2026 |
| 16 | Walleye Capital Llc | 21,680 | $314K | New | Mar 2026 |
| 17 | Hrt Financial Lp | 15,388 | $223K | New | Mar 2026 |
| 18 | Renaissance Technologies Llc | 11,948 | $173K | New | Mar 2026 |
| 19 | Thompson Davis & Co., Inc. | 11,750 | $170K | New | Mar 2026 |
| 20 | Bnp Paribas Financial Markets | 924 | $13K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 22,402 | $343K | Feb 2026 |
| 2 | Ultra-Small Company Market Fund | 10,000 | $145K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 6,664 | $102K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 5,475 | $84K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 2,987 | $46K | Feb 2026 |
| 6 | Guggenheim Active Allocation Fund | 3 | $46 | Feb 2026 |
Valuation
Market Cap
$131.0M
Enterprise Value
$183.5M
P/E (TTM)
-4.27x
Forward P/E
—
PEG Ratio
0.05x
P/B
—
P/S
1.36x
P/FCF
-5.57x
EV/EBITDA
—
Shares Out
7.6M
Financials (TTM)
Revenue
$96.1M
Net Income
-$32.0M
EBITDA
-$18.3M
Free Cash Flow
-$23.5M
Op Cash Flow
-$23.3M
EPS Basic
$-4.67
EPS Diluted
$-4.06
EPS Forward
$-3.07
Gross Margin
82.1%
Op Margin
-25.9%
Net Margin
-33.3%
Balance Sheet
Total Assets
$87.5M
Total Liab.
$89.9M
Total Equity
-$2.5M
Cash
$19.0M
LT Debt
$71.5M
Book Value/Sh
$-0.33
Debt/Equity
-29.56x
Current Ratio
1.86
Quick Ratio
1.86
Returns & Growth
ROE
1430.6%
ROA
-40.3%
ROIC
-39.0%
Rev Growth YoY
+24.1%
EPS Growth YoY
+29.2%
Price Returns
2W
+10.6%
1M
+48.6%
3M
+6.5%
6M
+97.1%
12M
+170.2%
Technicals
52W High
$19.40
52W Low
$5.01
50d MA
$14.08
200d MA
$10.85
RSI (14)
64.70
ATR (14)
$1.07
Beta
0.57
Avg Volume
54K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.67
High
$20.00
Low
$3.00
Median
$3.00
Data updated apr 24, 2026 9:03pm
· Source: financialmodelingprep.com